CUSIP: 64132K102
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
9,274,985
-
Share change
-
-848,554
-
Total reported value
-
$1,716,550
-
Price per share
-
$0.18
-
Number of holders
-
34
-
Value change
-
-$156,228
-
Number of buys
-
9
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 64132K102?
CUSIP 64132K102 identifies NBSE - NEUBASE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 64132K102:
Institutional Holders of NEUBASE THERAPEUTICS INC - COM (NBSE) as of Q1 2023
As of 31 Mar 2023,
NEUBASE THERAPEUTICS INC - COM (NBSE) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,274,985 shares.
The largest 10 holders included
GREENLIGHT CAPITAL INC, Point72 Asset Management, L.P., Decheng Capital Management III (Cayman), LLC, CARNEGIE MELLON UNIVERSITY, Polar Asset Management Partners Inc., Kestra Advisory Services, LLC, VANGUARD GROUP INC, JACOB ASSET MANAGEMENT OF NEW YORK LLC, PRELUDE CAPITAL MANAGEMENT, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.